Global controls
The core model results are uncrowded and represent an expected-launch development cohort. A separate tab explores optional, uncalibrated commercial crowding assumptions.
Load your own parameters
Upload an Excel workbook to replace the reference phase values, scenario multipliers (including AI-B execution only), modality adjustments, therapeutic-area substitutions, commercial archetypes and V cases. The optional Crowding sheet controls only Tab 5. Download the template below, edit it, and upload it back; missing or empty sheets are left unchanged.
Pipeline picture
Selected scenario summary
Decision quality is not the same as progression: a good early-stage decision may stop an ineffective medicine before Phase III without raising the observed phase pass rate. The eight-stage model does not classify true and false positive/negative decisions.
Corrected historical comparator
Phase-level computed results
Shapley decomposition of the change since 2010
Exact grouped Shapley attribution of the difference in capitalized cost between the corrected inflation-adjusted Paul et al. comparator and the selected scenario at the current discount rate. Groups: discovery/preclinical unit costs, clinical/regulatory unit costs, cycle times and transition probabilities. Contributions include interaction effects and sum exactly to the total change.
Tornado sensitivity plots
The manuscript Figure 3 uses the phase-specific audited evidence envelopes, not an arbitrary ±20% change in all parameters. For forward scenarios and optional product-type/therapeutic-area overrides, envelope endpoints are shifted or scaled consistently around the selected reference. These are sensitivity bounds, not estimated probabilities or achievable improvements. A separate custom percentage-stress mode remains available for exploration; it is not the paper figure. The value tornado varies peak gross profit ±20% and the discount rate over the selected range.
Editable R&D phase values for the selected scenario
Editable scenario transformations
Forward scenarios transform phase costs, times and progression probabilities. AI-A assumes moderate execution gains but no higher progression. AI-B execution only applies full AI-B cost/time multipliers but retains reference progression rates; full AI-B then adds explicitly hypothetical transition increases. China applies development-time changes only, not changes in global asset supply, sourcing or selection; AI-A + China uses the faster time multiplier in each overlapping phase without double counting. Progression is an observed cohort statistic, not a direct measure of decision quality. All cells are editable.
Editable modality-specific R&D adjustments
Optional R&D overlay by product type. The manuscript withdrew the universal biologic R&D modifier used in the original submission, so the biologic row defaults to no change (Phase III cost ×1.0, Δp(TS) = 0) and biologics differ only through the commercial archetype. The rows for monoclonal antibodies, CAR-T, siRNA/RNAi and gene therapy substitute BIO modality transition rates for the four clinical phases and are transition-rate robustness checks, not full modality cost models. All cells are editable.
Editable therapeutic-area substitutions
Applied on top of the selected scenario and product type. The four clinical p(TS) values replace the scenario's clinical transition probabilities (a blank cell leaves the scenario value unchanged); the cost multipliers scale Phase I–III cost per program and default to 1. The first row is the canonical all-therapeutic-area reference and is a no-op. All cells are editable, and the selected therapeutic area drives every figure and table in the app.
Run data, as text (for scripts and AI agents)
| Phase I starts per launch | |
|---|---|
| Paul comparator OOP / launch | |
| Paul comparator capitalized cost | |
| Paul comparator launch time | |
| Paul comparator launch probability | |
| Shapley: discovery/preclinical unit costs | |
| Shapley: clinical/regulatory unit costs | |
| Shapley: cycle times | |
| Shapley: transition probabilities | |
| Shapley: total change | |
| Tornado: capitalized cost | |
| Tornado: PV of R&D at Target-to-Hit | |
| Tornado: cohort NPV at V | |
| Phase-level results |
Drive this page from code through window.sims (see the JSON block script#sim-manifest), or without code: load it with ?scenarioSelect=China%20execution&discountRate=9 and read the result below. Other demos: add demo=value, demo=uncertainty, demo=robustness or demo=crowding.
Expected-launch cohort R&D-cost recovery
Core calculation (without crowding): the discounted modeled gross-profit stream from one expected successful launch minus the R&D expenditure required, on average, to produce one launch. Gross profit means net sales less cost of goods sold. Selling, marketing, administration, taxes, acquisitions/licensing, postapproval investment and other organizational costs are excluded. This is not the expected NPV of an individual Target-to-Hit candidate or complete firm-level profitability.
NPV table by scenario and product type
Mature annual gross-profit assumptions are editable below. Core NPV calculations are always uncrowded. The separate Theoretical crowding tab explores conditional reductions in producer value.
Break-even V
Editable commercial lifecycle values
Years to peak and competition onset are anchored to observed market behavior (Wouters et al., 2024a,b); the erosion parameters and horizon are model assumptions. Editing a value immediately updates all curves and tables.
Editable V cases
These values set the columns in the NPV table and the x-values in the NPV chart.
Protection-window check
Equations implemented
R&D model
OOP_i = WIP_i · C_i
m_i = Σ_{k<i} T_k + T_i/2 ; L = Σ_i T_i
PV0_R&D = Σ_i OOP_i / (1+r)^{m_i}
CAP_launch = Σ_i OOP_i · (1+r)^{L-m_i} = PV0_R&D · (1+r)^L
Scenario s: C_i = C_i^ref · m^C_{i,s} ; T_i = T_i^ref · m^T_{i,s} ; p_i = clip(p_i^ref + Δp_{i,s})
Commercial model
U(a) = min(1, a / t_peak)
E(a) = 1, a ≤ M ; E(a) = F + (1−F)·exp(−λ(a−M)), a > M ; λ = −ln(0.05)/d
M = observed competition onset (base archetype)
GP(t;V) = V · U(a) · E(a) · 1_{t≥L}
Cohort NPV0(V) = ∫_0^{L+H} GP(t;V)/(1+r)^t dt − PV0_R&D ; V* = PV0_R&D / PV_GP(V=1)
Gross profit = net sales − cost of goods sold; excludes commercial overhead and other unmodeled costs
Export
Run data, as text (for scripts and AI agents)
| Commercial archetype | |
|---|---|
| Launch year | |
| Peak year | |
| Competition onset year | |
| V cases | |
| NPV by product type and scenario | |
| Break-even V by scenario and product type | |
| Protection-window check |
Without code: load the page with ?demo=value&peakV=2. The scenario, product type, therapeutic area and rate are parameters of demo pipeline.
Frozen 2026 probabilistic reference and scenario propagation
The 24 phase parameters (8 costs, 8 cycle times, 8 transition probabilities) are treated as uncertain conditional on explicitly selected evidence and distributions. Twenty thousand simulated draws do not identify an industry-wide probability distribution or establish source-family weights. Draws use evidence-quality-specific distributions: empirical calendar-year vector bootstrap for A-rated clinical time and p(TS), a source-family mixture of lognormals for B-rated clinical costs, beta-PERT distributions for weaker discovery/preclinical inputs, and a correlated discovery-success constraint. Each scenario's transformation (and the current product-type and therapeutic-area selection) is applied to the same base draw, so scenario comparisons are paired. With the default settings (seed 20261002, 20,000 draws, 11%, small molecule, canonical therapeutic area) the results reproduce the frozen run reported in the manuscript and Supplementary Information.
Deterministic reference and probabilistic outputs — selected scenario
Scenario propagation across the same draws
Source-conditioned capitalized cost (manuscript Figure 2a)
Audited 24-parameter specification
Evidence grade: A = recent/direct data with a close definition match; B = direct empirical evidence with substantial source heterogeneity; C = indirect or imperfectly mapped evidence; D = legacy/heuristic evidence with little contemporary phase-specific public data. Ranges are evidence envelopes, not confidence intervals.
Source-family weighting is a modeling convention and the output interval is conditional on the assumptions; it is not a measured or confidence-bounded industry cost distribution.
Modeling assumptions for uncertainty
Clinical time: one IQVIA calendar-year vector from 2020–2024 is sampled jointly across Phases I–III and regulatory review, preserving observed cross-phase year effects.
Clinical p(TS): one Citeline/IQVIA calendar-year vector from 2021–2025 is sampled jointly across Phases I–III and regulatory submission.
Discovery/preclinical p(TS): phase-specific beta-PERT draws are shifted together on the logit scale so their product matches a sampled discovery-to-clinic yield, modeled as beta-PERT(0.20, 0.32, 0.45). This keeps the model near the point-reference product (30.5%) while respecting the published ~34% industrial discovery-to-clinic estimate as an external calibration.
Scenarios: the multipliers and transition-success increments of each scenario are applied to the base draw at runtime; the break-even values propagate the draw through the selected commercial archetype with commercial assumptions held fixed.
Export uncertainty results
Run data, as text (for scripts and AI agents)
| Draws so far | |
|---|---|
| Scenario summarized | |
| Capitalized cost per launch, median | |
| Capitalized cost, 5th percentile | |
| Capitalized cost, 95th percentile | |
| Out-of-pocket cost per launch, median | |
| Target-to-launch time, median | |
| Target-to-launch time, 5th percentile | |
| Target-to-launch time, 95th percentile | |
| Launch probability, median | |
| Launch probability, 5th percentile | |
| Launch probability, 95th percentile | |
| Break-even V, median | |
| Break-even V, 5th percentile | |
| Break-even V, 95th percentile |
Without code: load the page with ?demo=uncertainty&seed=20261002&steps=20000&autorun=1 (one step is one paired draw) and wait for html[data-sim-status="done"].
The analyses on this tab reproduce manuscript Figures 4 and 5 and the China timing bounds in Supplementary Part S2. They use the current reference phase values and scenario transformations, and the selected product type and therapeutic area, at the discount rate shown in each panel.
Cells are capitalized cost ($B) when all phase durations are scaled by a common multiplier and the rate is varied. The reference cell is in bold.
Mathematical progression-rate stress test, not a model of decision quality. Early rejection of ineffective candidates can save downstream spending even if measured progression falls; false-negative rejection of useful candidates must also be considered. Phase I progression is raised while Phase II progression declines.
Every therapeutic area in the editable table, with cost and time held at the selected scenario's values. Values are editable on the Pipeline tab.
Not a full modality cost model. CAR-T, RNA and gene therapy have materially different manufacturing, preclinical and clinical economics. Monoclonal-antibody preclinical cost is varied 1–2× as a robustness check.
Strictly hypothetical additional attrition after all exits already embedded in empirical transition rates; not a correction to baseline success and not derived from the fraction of discontinued trials stopped for commercial reasons.
China execution timing bounds (Supplementary Part S2)
These exploratory phase-time reductions describe only one execution channel. The simulation does not quantify China's expanded sourcing network, clinical capacity, earlier human evidence, asset selection or cross-border value capture. No default success-rate or per-program cost advantage is assigned to China.
Run data, as text (for scripts and AI agents)
| Capitalized cost of the selected arrays | |
|---|---|
| Capitalized cost and break-even V by rate (4a) | |
| Cycle-time x rate grid (4b) | |
| Risk shifting (5a) | |
| Therapeutic-area substitution (5b) | |
| Modality substitution (5c) | |
| Additional discontinuation (5d) | |
| China execution timing bounds |
Without code: load the page with ?demo=robustness&riskPhaseIpp=5. The two comma-separated lists are set with sims.robustness.setData().
Theoretical crowding: optional market-value sensitivity
The revised manuscript discusses competitive crowding qualitatively (Section 5.5). Supplementary Section 6 and Supplementary Figure S2.2 provide an illustrative equal-share model; this interactive tab additionally includes uncalibrated launch-order, price-erosion and differentiation-window extensions. An increasing number of pipeline assets is not the same as an increasing number of independently marketed products, and neither necessarily implies that commercial profit is already being diluted. The incretin market illustrates strong category expansion despite competitive rivalry. Reduced producer profit can coexist with improved affordability, access and health outcomes.
Optional entry-order and price-erosion extensions
These controls apply only in this theoretical tab; they do not change the published pipeline, core NPV, or Monte Carlo values. The initial V is the stand-alone mature annual gross-profit opportunity, and the conditional realized V equals V × Φ. The equal-share benchmark sets φ = 1, π = 0 and no early end to differentiation. The more speculative optional extensions allow order-of-entry advantages (φ), net-price erosion (π), and a shortening of effective differentiation (D). None of these parameters has been estimated from market data. Choosing N = 1 recovers the uncrowded model.
Equal-share model (Supplementary Figure S2.2)
Break-even stand-alone peak gross profit required per entrant for the selected scenario, product type and discount rate, as the number of entrants N increases, for category-expansion exponents β = 0.5, 0.8 and 1.0: V*(N) = V*(1) · N1−β. This is the uncalibrated model in Supplementary Section 6, not a main-text result. The β values are illustrative sensitivities, not estimated from observed class economics. Competitors may expand category size and patient access even if producer returns per product eventually decline.
Conditional producer-value counterfactual
Each forward scenario is compared with the uncrowded reference, then with its own uncrowded R&D gains, and finally with the same hypothetical crowding penalty applied. These are conditional producer-side value stress tests, not forecasts or estimates of realized market saturation. The China scenario in particular covers only development time; expanded sourcing and capacity are outside the model.
Model equations and definitions
Supplementary equal-share model and additional extensions
Φ(N,n) = N^β · s(n,N) · (1−π)^{N−1}
s(n,N) = φ^{n−1} / Σ_{j=1..N} φ^{j−1} (equal shares when φ = 1)
Equal-share benchmark: Φ = N^{β−1} ; V*_N = V*_1 · N^{1−β}
Terms
N products launched into the crowded area; n this program's order of entry. β category-expansion exponent (β = 1 means total category value grows in proportion to entry, so no dilution under equal shares; β = 0 is a fixed pie). φ rank share decay, giving earlier entrants a durable share advantage. π net-price give-up per additional entrant. D years of economic differentiation after launch, which caps the protected period. t_peak years to peak, M competition onset after launch, F residual floor, d years to reach 95% of the post-competition decline, H commercial horizon.
Export the theoretical stress test
This CSV includes the selected scenario and every comparison, with uncrowded and conditional crowded cohort NPV side by side. It is not the frozen paper input or a calibrated market forecast.
Run data, as text (for scripts and AI agents)
| Crowding multiplier Φ | |
|---|---|
| Realized peak V | |
| Conditional cohort NPV | |
| Uncrowded cohort NPV | |
| Break-even perceived V | |
| Uncrowded break-even V | |
| Protected years after launch | |
| Differentiation window binds | |
| Cohort NPV versus entrants | |
| Entrants at which NPV turns negative | |
| Φ by order of entry | |
| Equal-share model | |
| Conditional producer-value counterfactual |
Without code: load the page with ?demo=crowding&crowdN=6&crowdPhi=0.7.
Instructions manual
This page explains what the tool computes, how to use each tab, how to load your own parameters, and how to reproduce the numbers in the manuscript. Costs are in 2025 US dollars (millions in the phase tables, billions in the summaries). Every result on every tab is recalculated from the current parameters whenever a control or an editable cell changes.
Contents
- What the model does
- Global controls
- Tab 1: Pipeline model
- Tab 2: Core cohort value
- Tab 3: Uncertainty
- Tab 4: Sensitivity & robustness
- Tab 5: Theoretical crowding stress tests
- Loading your own parameters (Excel)
- Exports and figures
- Reproducing the manuscript numbers
- Interpretation notes and common questions
Quick start
- Leave the global controls at their defaults (2026 reference, small molecule, no therapeutic-area substitution, 11%, V = $5B/year). The Pipeline tab then shows the manuscript's reference case: $2.33B out-of-pocket, $5.25B capitalized, 14.4 years, 2.31% launch probability.
- Change the scenario to see the AI and China cases; change the product type or therapeutic area to apply overlays.
- Open Tab 2 for core expected-launch cohort value and R&D break-even gross profit; Tab 5 contains optional, uncalibrated crowding scenarios.
- Open Tab 3 and press Run Monte Carlo (about 10–20 seconds) for uncertainty envelopes.
- Edit any yellow cell to change an assumption; press Reset to manuscript defaults to return.
1. What the model does
The tool implements the eight-stage pipeline model of the article. Each stage i (Target-to-Hit, Hit-to-Lead, Lead Optimization, Preclinical, Phase I, Phase II, Phase III, Submission-to-Launch) has three parameters: cost per program entering the stage (Ci), start-to-next-stage duration (Ti) and transition success (pi). From these it computes, for one expected launch:
- Programs per launch at each stage (1 / product of downstream transition probabilities) and the launch probability (product of all eight pi).
- Out-of-pocket cost per launch: the sum over stages of cost per program times programs per launch.
- Capitalized cost per launch: the same cash flows compounded to the launch date at the discount/capitalization rate, assuming each stage's spend occurs at its midpoint. PV of R&D at Target-to-Hit is the same quantity discounted to program start.
- Expected-launch cohort NPV and R&D break-even gross profit (V*): a modeled net-sales-minus-COGS stream for one expected successful launch minus the expected R&D expenditure of the portfolio required for that expected launch. It does not deduct marketing, sales, administration, taxes, transactions or postapproval R&D. It is neither a single-candidate NPV nor complete business profitability.
The 2026 reference is the audited parameter set of Table 1 in the article. The five forward scenarios (AI-A efficiency, AI-B execution only, AI-B predictive validity, China execution, AI-A + China) are not separate parameter sets: each is a vector of phase-specific cost multipliers, time multipliers and additive transition-success changes applied to the reference at run time. Editing the reference therefore moves every scenario. The Paul et al. (2010) corrected comparator is an absolute-value scenario (inflation-adjusted, 13.5-year cycle) kept for historical comparison; it does not inherit reference edits. The Equations panel on Tab 2 gives all formulas.
2. Global controls
| Control | What it does | Default |
|---|---|---|
| R&D scenario | Selects the parameter set shown on Tabs 1 and 2, the scenario whose histograms are shown on Tab 3, and the scenario used by the grid, risk-shifting, therapeutic-area and modality panels on Tab 4. Tables that compare scenarios always show all of them. | 2026 reference |
| Product type / commercial archetype | Chooses the commercial lifecycle archetype (small molecule or biologic) and any R&D overlay defined for that product type in the modality table on Tab 1. Small molecule and Biologic carry no R&D overlay by default; Monoclonal antibody, CAR-T, siRNA/RNAi and Gene therapy substitute BIO modality transition rates for the four clinical stages. | Small molecule |
| Therapeutic area | Replaces the four clinical transition probabilities with BIO/QLS/Informa 2011–2020 values for that area (cost and time unchanged). The first entry is a no-op. | All-TA canonical reference |
| Discount / capitalization rate | The rate used for capitalization, discounting and NPV on Tabs 1, 2 and 4. Tab 3 has its own comparison rate. | 11% |
| Selected mature gross profit V | Annual gross profit (net sales minus cost of goods sold) for one successful launch. Core calculations apply no crowding; Tab 5 interprets the same amount as a hypothetical stand-alone opportunity. | $5B/year |
The line under the controls summarizes the current core selection without crowding. Assumption overlays stack in a fixed order: scenario transformation, then product-type adjustments, then therapeutic-area substitution. The theoretical crowding controls apply only to Tab 5.
3. Tab 1: Pipeline model
| Panel | Contents and use |
|---|---|
| Pipeline picture | The Paul-style funnel for the current selection: capitalized and out-of-pocket cost per launch by stage, share of total cost, cycle time, cost per program, programs needed per launch and p(TS). The header gives the totals. Download as PNG with the button. |
| Selected scenario summary | The five headline metrics (OOP, capitalized cost, PV of R&D at Target-to-Hit, launch probability with Phase I starts per launch, launch time) and, below them, the corrected Paul et al. comparator at the current rate for side-by-side comparison. |
| Phase-level computed results | Effective (post-overlay) parameters and the stage-by-stage accounting, with totals. |
| Shapley decomposition | Exact grouped Shapley attribution of the change in capitalized cost from the Paul comparator to the selected scenario, in four groups: discovery/preclinical unit costs, clinical/regulatory unit costs, cycle times, transition probabilities. Contributions include interaction effects and sum to the total. With the reference selected this reproduces Figure 2b (+$1.51B transitions, +$0.74B clinical costs, +$0.34B cycle times, ≈0 discovery). |
| Tornado sensitivity plots | Default: one-at-a-time evidence-envelope sensitivity of all 24 phase parameters, the method in revised Figure 3. The exploratory custom relative-stress mode is separate and not used in the paper. Three outputs: capitalized cost, PV of R&D and expected-launch cohort NPV. Peak V uses ±20% and the discount rate 9–13% by default. |
| Editable R&D phase values | With the reference or the Paul comparator selected: the absolute cost, time and p(TS) per stage, editable. With a forward scenario selected: a read-only view of reference value, multiplier and effective value for each stage. |
| Editable scenario transformations | For each forward scenario and stage, three stacked cells: cost multiplier, time multiplier, Δp(TS) in percentage points. Edit these to redefine a scenario. |
| Editable modality-specific R&D adjustments | Per product type: commercial archetype, preclinical and Phase III cost multipliers, optional clinical p(TS) substitutions (blank = keep scenario value) and additive Δp(TS) for the clinical stages. Use this, for example, to restore a biologic Phase III cost premium. |
| Editable therapeutic-area substitutions | Per therapeutic area: the four clinical p(TS) values and Phase I–III cost multipliers. |
4. Tab 2: Core expected-launch cohort value
| Panel | Contents and use |
|---|---|
| Current scenario uncrowded cohort value | Expected-launch cohort NPV at Target-to-Hit for V, discounted gross profits, modeled R&D cohort cost, R&D break-even V and launch timing, always without crowding. |
| Uncrowded cohort NPV versus mature gross profit | One line per scenario at the selected product type and therapeutic area; x-values are the V cases. The marker on the zero line is each scenario's break-even V. Reproduces Figure 7a. |
| Commercial gross-profit lifecycle | Uncrowded gross-profit assumptions for one expected successful launch on the absolute program timeline. Gross profit means net sales minus cost of goods sold; selling, general overhead, tax and transactions are excluded. |
| Uncrowded NPV and R&D break-even V tables | All scenarios × product types at the chosen V cases, with modeled cohort NPV and the annual gross profit needed to recover expected R&D expenditure; excludes commercial overhead. |
| Editable commercial lifecycle values | Per archetype: years to peak, competition onset after launch, residual floor, years to reach 95% of the decline, horizon. Defaults are the Table 4 values (8/12.6 years for small molecules, 13/20.3 years for biologics). |
| Editable V cases | The V values used as NPV table columns and chart x-values. |
| Protection-window check | Launch year, peak year and assumed competition onset for each commercial archetype. Any discretionary earlier differentiation window applies only in the separate theoretical crowding tab. |
| Core equations implemented | The R&D, commercial and crowding formulas as coded. |
5. Tab 3: Uncertainty
The Monte Carlo treats the 24 reference parameters as uncertain. Each draw samples all 24 jointly (clinical costs from one of three source families, clinical times and transition rates from one calendar-year vector each, discovery-stage parameters from beta-PERT distributions with a correlated discovery-to-clinic yield), then applies every scenario's transformation and the current product-type and therapeutic-area overlays to that same draw, so scenario comparisons are paired. Break-even values propagate each draw through the selected commercial archetype with commercial parameters held fixed.
| Element | Use |
|---|---|
| Draws, seed, comparison rate | Defaults 20,000 / 20261002 / 11% reproduce the frozen manuscript run. Fewer draws run faster but change the percentiles slightly. The run processes draws in batches to keep the interface responsive; the status line shows progress and completion. |
| Deterministic reference and probabilistic outputs | Headline metrics and a summary table (point value, mean, P05, P25, median, P75, P95) for the selected scenario. Change the scenario in the global controls to switch without re-running. |
| Histograms | Capitalized cost, cycle time and launch probability for the selected scenario, with the median (solid) and 5th/95th percentiles (dashed). |
| Scenario propagation | Dot-and-interval chart and table of medians and 5–95% envelopes for capitalized cost, time, launch probability and break-even V across all scenarios; ticks mark deterministic values. Reproduces Figures 6 and 7b and Tables 3 and 5. |
| Source-conditioned capitalized cost | Box plots of capitalized cost by clinical-cost source family (ASPE/ERG, DiMasi, Wouters-derived) for the selected scenario; reproduces Figure 2a. |
| Audited 24-parameter specification | Reference value, evidence envelope, quality grade, sampling distribution and rationale for each parameter (Table 1 and Supplementary Part S1). |
Results are cached until a parameter that affects them changes (reference values, scenario multipliers, product-type or therapeutic-area tables, commercial values, the product-type or therapeutic-area selection, or the comparison rate). Editing V, the V cases or the separate theoretical crowding overlay does not invalidate the run.
6. Tab 4: Sensitivity & robustness
| Panel | Contents |
|---|---|
| Capitalized cost by rate (Figure 4a) | All scenarios at 7, 9, 11 and 13%, with break-even V at each rate in the table. |
| Cycle-time × rate grid (Figure 4b) | Capitalized cost for the selected scenario when all phase durations are scaled by 0.8–1.2 and the rate is varied 7–15%. The current cell is outlined. |
| Risk shifting (Figure 5a) | Phase I p(TS) raised by the stated amount while Phase II is reduced by each listed offset; the Phase I×II progression and capitalized cost show whether an early-stage gain survives downstream. Both inputs are editable. |
| Therapeutic-area substitution (Figure 5b) | Capitalized cost for every therapeutic area in the editable table, sorted; the selected area is bold. |
| Modality substitution (Figure 5c) | Capitalized cost for every product type; monoclonal antibodies are also shown with preclinical cost at 1×, 1.5× and 2×. |
| Commercial / portfolio discontinuation (Figure 5d) | Additional nontechnical attrition after the technical-regulatory chain, applied as a continuation factor on the final stage; the listed percentages are editable. |
| China execution timing bounds | The low/mid/high phase-timing reductions behind the China scenario (Supplementary Part S2) next to the time multipliers currently in the scenario table. |
7. Tab 5: Theoretical crowding
Separate from the article's uncrowded economic calculations. Supplementary Section 6 presents only the simplified equal-share benchmark; this tab also retains more speculative entry-rank advantages, price erosion and shortened differentiation. All are uncalibrated assumptions. No model output from this tab is an empirical statement about market saturation. Enter N = 1 to recover core gross-profit value. The tab has its own export containing the conditional and uncrowded cohort results side by side.
Therapeutic category expansion can coexist with pipeline herding and commercial rivalry. Lower producer profits may correspond to lower patient prices and increased access; those consequences are not valued by this model.
| Panel | Interpretation |
|---|---|
| Theoretical crowding extension (Tab 5) | The optional theoretical stress-test overlay (Tab 5). Entrants N is the number of products launched into the class (1 = no crowding). Expansion β sets how total class value grows with N (Nβ). With share decay φ = 1 and price erosion π = 0 (the defaults) every entrant receives an equal share and the multiplier is Φ = Nβ−1, the supplementary equal-share benchmark. Setting φ < 1 gives earlier entrants a larger share (then Order of entry n matters); π > 0 adds per-entrant price erosion; Differentiation window D ends economic exclusivity D years after launch if that is earlier than the observed competition onset; the floor and years-to-floor overrides replace the archetype's erosion parameters. The metrics, the NPV-versus-N chart and the share-by-rank chart update with every edit. |
| Equal-share theoretical sensitivity (Tab 5) | Break-even stand-alone V per entrant for N = 1 to 20 and β = 0.5, 0.8, 1.0, for the current selection; corresponds to Supplementary Figure S2.2 and the $1.76B/$1.95B (β = 0.8) and $3.02B/$3.90B (β = 0.5) values at N = 6 and 10. |
| Conditional producer-value stress test (Tab 5) | For each forward scenario: (1) the reference, (2) the scenario's R&D gains with V uncompressed, (3) the same R&D with the separate theoretical crowding overlay applied. The R&D columns improve from step 1 to 2 while the NPV column falls from step 2 to 3 when N > 1. Raise N in the overlay to see the effect. |
8. Loading your own parameters (Excel)
Press Download Excel template (current values) on the main page to get a workbook containing every editable assumption as it currently stands. Edit it and upload it with Upload parameters. Sheets are matched by name (case and spacing are ignored); any sheet that is missing or empty leaves the corresponding assumptions unchanged, and rows with unrecognized names are skipped. Percentages may be entered as 0.47 or 47. The status line reports what was loaded.
| Sheet | Columns | Notes |
|---|---|---|
| Reference | Scenario, Phase, Cost_per_program_M, Cycle_time_y, pTS | Rows for "2026 reference" edit the reference. Rows with any other scenario name create or edit an absolute-value scenario (used for the Paul comparator). |
| Scenarios | Scenario, Phase, Cost_multiplier, Time_multiplier, dpTS_pp | One row per scenario and phase. New scenario names create new forward scenarios; unlisted phases keep multiplier 1 and Δp(TS) 0. |
| Modality | Product_type, Archetype, Preclinical_cost_multiplier, Phase3_cost_multiplier, pTS_PhaseI…pTS_Submission, dpTS_PhaseI_pp…dpTS_Submission_pp | Blank pTS cells keep the scenario's clinical values. Archetype must match a row of the Commercial sheet. |
| TherapyAreas | Therapeutic_area, pTS_PhaseI…pTS_Submission, Cost_mult_PhaseI…Cost_mult_PhaseIII | New names add areas to the selector. |
| Commercial | Archetype, Years_to_peak, Competition_onset_y, Residual_floor_pct, Years_to_floor, Horizon | New archetype names can be referenced from the Modality sheet. |
| Crowding | Parameter, Value | Entrants_N, Rank_n, Expansion_beta, Share_decay_phi, Price_erosion_pi, Diff_window_y, Residual_floor, Years_to_floor (blank = archetype value). |
| Settings | Setting, Value | Discount_rate_pct, Selected_peak_V_B, Selected_scenario, Selected_product_type, Selected_therapeutic_area, V_case_1 … V_case_n. |
Phase names are matched flexibly ("Phase I", "phase 1", "Lead Optimization", "LO" all work). Uploading clears any cached Monte Carlo run. Reset to manuscript defaults discards all edits and uploads.
9. Exports and figures
- ⬇ PNG buttons next to every chart save that chart at twice its on-screen resolution; file names encode the scenario, product type and therapeutic area.
- Download core cohort results CSV (Tab 2): uncrowded cohort NPV, modeled R&D break-even and pipeline metrics for every scenario × product type × V case.
- Download exploratory crowding CSV (Tab 5): conditional stress-test values alongside uncrowded comparisons; not part of the frozen evidence.
- Download selected phase results CSV: the phase-level table for the current selection.
- Download assumptions JSON: every current parameter table and setting, for a complete record of an analysis.
- Download model specification JSON (Tab 3): the frozen manuscript specification, including the sampling distributions.
- Download last Monte Carlo draws CSV: one row per draw with source family, calendar-year vectors, discovery yield and the reference-scenario outputs.
- Download scenario MC summary CSV: medians and 5–95% envelopes per scenario, in the same layout as the manuscript's
scenario_mc_summary.csv.
10. Reproducing the manuscript numbers
| Manuscript item | Where in the tool | Settings |
|---|---|---|
| Table 1 / Figure 1 (reference case: $2.33B OOP, $5.25B capitalized, 14.4 y, 2.31%, 13.2 Phase I starts) | Tab 1, pipeline picture and summary | Defaults |
| Corrected Paul comparator (13.5 y, $2.67B) and Figure 2b Shapley decomposition | Tab 1, comparator box and Shapley panel | Reference selected, 11% |
| Table 2 / Table 3 deterministic scenario results (AI-A $4.47B, AI-B execution only $3.45B, full AI-B $2.47B, China $4.85B, combined $4.37B) | Tab 1 (select each scenario) or Tab 2 break-even table | Defaults |
| Figure 2a and Table 3 uncertainty column (reference median $4.98B, $2.50–$8.84B) | Tab 3 after Run Monte Carlo | 20,000 draws, seed 20261002, 11%, small molecule, canonical therapeutic area |
| Figure 3 evidence-bounded tornados | Tab 1 tornado panel | Audited evidence bounds; rate 9–13%; V = $5B |
| Figure 4 rate and cycle-time sensitivity | Tab 4 | Defaults |
| Figure 5 robustness panels | Tab 4 | Reference selected |
| Figures 6 and 7b, Table 5 (six scenarios, including AI-B execution only $3.27B cost median and $0.77B/y modeled R&D break-even median) | Tab 3 scenario propagation | 20,000 paired draws, seed 20261002, canonical product/TA |
| Figure 7a and Table 4/5 deterministic break-even ($1.23B reference) | Tab 2 | Defaults |
| Supplementary Figure S2.2 (illustrative crowding model) | Tab 5 equal-share panel | Reference selected; N as plotted; β = 0.5/0.8/1.0 |
The Monte Carlo engine (Mulberry32 generator, draw order and distributions) is the same as in the Python model of the reproducibility package, so medians and percentiles agree to the third decimal. Running with a different product type or therapeutic area applies that overlay to every draw; the manuscript figures use small molecule and the canonical therapeutic area.
11. Interpretation notes and common questions
- Why does editing a forward scenario's phase values not work? Forward scenarios are transformations of the reference. Edit the reference values (select "2026 reference") or the multipliers in the scenario-transformation table.
- Why are Small molecule and Biologic R&D numbers identical? The manuscript withdrew the universal biologic R&D modifier; biologics differ through the commercial archetype (longer uptake, later competition, higher floor). Add a Phase III cost multiplier or Δp(TS) in the modality table if you want an R&D overlay.
- Why is the discovery contribution in the Shapley decomposition near zero? Discovery-stage unit costs in the reference are the inflation-adjusted Paul values, so there is no change to attribute; the manuscript labels these inputs grade D and bounds them in the Monte Carlo.
- Which rate should I use? 11% is retained for comparability with the 2010 benchmark and is an analysis setting rather than an audited parameter; Tab 4 shows every scenario at 7–13% and the grid to 15%.
- What does Φ mean? The share of the stand-alone peak gross profit a product realizes when N products share the class. With equal shares Φ = Nβ−1; β is illustrative, not calibrated, because public class histories do not identify it.
- Why do the theoretical counterfactual steps 2 and 3 agree? In Tab 5 the default is N = 1. Increasing N produces a hypothetical producer-value stress test, not an estimated market saturation threshold.
- Why did the Monte Carlo results disappear? You changed a parameter that affects the draws (reference values, scenario multipliers, overlay tables, commercial values, product type, therapeutic area or the comparison rate). Press Run Monte Carlo again.
- Are the therapeutic-area and modality results full cost models? No. They substitute clinical transition rates only (plus an optional preclinical cost multiplier for antibodies) and are robustness checks, as stated in the manuscript.
- Is anything stored? Nothing leaves the browser. Edits are lost when the page is reloaded; use the Excel template or the assumptions JSON to keep a parameter set.